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Purpose: To evaluate the usefulness of the TonoVet™ rebound tonometer in measuring intraocular pressure (IOP) of
monkeys.
Methods: The accuracy of the TonoVet™ rebound tonometer was determined in cannulated eyes of anesthetized rhesus
monkeys where IOP was controlled by adjusting the height of a connected perfusate reservoir. To assess the applicability
of the equipment through in vivo studies, the diurnal fluctuation of IOP and effects of IOP-lowering compounds were
evaluated in monkeys.
Results: IOP readings generated by the TonoVet™ tonometer correlated very well with the actual pressure in the
cannulated monkey eye. The linear correlation had a slope of 0.922±0.014 (mean±SEM, n=4), a y-intercept of 3.04±0.61,
and a correlation coefficient of r2=0.97. Using this method, diurnal IOP fluctuation of the rhesus monkey was demonstrated.
The tonometer was also able to detect IOP changes induced by pharmacologically active compounds. A single topical
ocular instillation (15 μg) of the rho kinase inhibitor, H1152, produced a 5–6 mmHg reduction (p<0.001) in IOP, lasting
at least 4 h. In addition, topical administration of Travatan®, a prostaglandin agonist, induced a small transient IOP increase
(1.1 mmHg versus vehicle control; p=0.26) at 2 h after treatment followed by a pressure reduction at 23 h (−2.4 mmHg;
p<0.05). Multiple daily dosing with the drug produced a persistent IOP-lowering effect. Three consecutive days of
Travatan treatment produced ocular hypotension of −2.0 to −2.2 mmHg (p<0.05) the following day.
Conclusions: The rebound tonometer was easy to use and accurately measured IOP in the rhesus monkey eye.
Glaucoma leads to visual impairment and blindness in
millions of people each year [1]. Elevated intraocular pressure
(IOP) is a major risk factor of this disease. Unfortunately, the
pathogenic mechanism of the disease is still unclear. Many
animal models have been developed to study glaucoma at the
molecular,  cellular,  and  physiologic  levels  as  well  as  to
evaluate potential new treatments [2,3]. Among the various in
vivo models, non-human primates are of great value because
of their morphological and physiologic similarities to humans
[4].  Practically  all  clinically  approved  IOP-lowering
medications have been shown to lower IOP in the monkey
[5]. Development of novel IOP-lowering therapies also often
depends  on  critical  preclinical  findings  provided  by  the
monkey  model.  Therefore,  an  accurate,  reproducible,  and
convenient IOP assessment for the monkey is central to the
continuous success of glaucoma research. Equipments such
as the Goldmann applanation tonometer, pneumatonometer,
and  the  TonoPen™  applanation  tonometer  are  commonly
used for the purpose of measuring monkey IOP. However,
some such as the Goldmann tonometer and pneumatonometer,
albeit  accurate  and  popular,  are  cumbersome  to  use.  In
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contrast, the TonoPen™, although easy to use, was limited by
its accuracy [6,7]. There is clearly an unmet need for an
improved tonometer with excellent accuracy and convenience
as well usefulness for non-human primate IOP appraisal.
More  than  a  decade  ago,  a  novel  rebound  tonometer
(originally  called  induction/impact  tonometer)  was
introduced [8]. To measure IOP, a light weight magnetic probe
is aimed at and normal (perpendicular) to the center of the
cornea. When triggered, it is propelled by a solenoid toward
the cornea, impacts it, and rebounds. The deceleration of the
probe during the impact, which correlates with IOP, can be
monitored  by  the  voltage  change  induced  by  the  moving
magnetic probe. It was demonstrated that IOP values in 71
eyes of 36 patients obtained by this method compare well with
those obtained by the Goldmann tonometer [8]. Recently, two
hand-held  apparatuses  based  on  this  technical  principle
became  commercially  available  for  animal  studies,  the
TonoLab™ rebound tonometer intended for use in rodents and
the TonoVet™ tonometer for use in animals with bigger eyes.
Rodent IOP readings obtained by the TonoLab™ have been
reported  to  represent  the  actual  IOP  accurately  and
reproducibly [9,10]. The equipment was also reported to be
easy to use with minimal required training [9,10].
In the present study, we evaluated the accuracy of the
TonoVet™ tonometer for measuring IOP in rhesus monkeys.
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2196We compared IOP readings reported by the equipment with
actual IOP preset by anterior chamber cannulation, similar to
that performed in the rodents [9]. We also used the TonoVet™
to  measure  normal  diurnal  IOP  fluctuation  of  sedated
monkeys. Furthermore, we used the tonometer to monitor IOP
levels following ocular topical treatment with IOP-lowering
compounds, the rho kinase inhibitor H1152 and Travatan®
ophthalmic  solution,  an  ocular  hypotensive  medication
approved for use in humans. Our results demonstrated the
usefulness of the TonoVet™ for measuring IOP in rhesus
monkeys.
METHODS
Animals: Five male and five female rhesus monkeys (Macaca
mulatta), two to six years of age, were obtained from the
PingAn Monkey Breeding Base (Chengdu, China) through the
National Chengdu Center for Safety Evaluation of Drugs,
which is accredited by the Association for Assessment and
Accreditation  of  Laboratory  Animal  Care  International
(AAALAC  International).  All  animal  experiments  were
conducted in compliance with the ARVO Statement for the
Use  of  Animals  in  Ophthalmic  and  Vision  Research,  the
Guide for the Care and Use of Laboratory Animals (National
Research  Council),  and  under  the  supervision  of  the
Institutional Animal Care and Use Committee. One male and
one female (M1 and M2; Table 1) were used to validate the
accuracy  of  the  tonometer.  The  remaining  eight  monkeys
(M3–M10;  Table  1)  were  subjected  to  diurnal  IOP
measurements and drug effects on IOP. The animals were
housed under 12-h/12-h light/dark cycle with lights on starting
at  6:00  AM.  Food  and  water  were  available  ad  libitum.
Physical examinations including an ophthalmic examination
were conducted in all monkeys before the experiments to
exclude  potential  health  factors  that  might  affect  IOP
measurements.  Details  pertaining  to  each  monkey  are
described in Table 1.
Rebound tonometer: IOP was measured using the TonoVet™
rebound tonometer (Tiolat Oy, Helsinki, Finland) according
to  the  manufacturer’s  recommended  procedures.  The
equipment is programmed to average the IOP values of six
consecutive, acceptable measurements and produce a reading
of the mean IOP. In the following studies, five readings (each
a  mean  of  six  measurements;  a  total  of  30  separate
measurements)  were  obtained  under  each  condition.  The
tonometer was validated as described below before it was used
to assess IOP in subsequent studies.
Tonometer validation:  Monkeys M1 (six-year-old female)
and M2 (six-year-old male) were anesthetized by intravenous
injection of pentobarbital sodium (40 mg/kg; Sigma-Aldrich
China, Shanghai, China). With the animals lying on their
sides,  anterior  chamber  cannulation  was  performed
consecutively on both eyes by inserting a 30-gauge needle
through the cornea into the anterior chamber. The needle was
connected via polyethylene tubing to a three-way connector,
which  was  connected  in  parallel  to  a  pressure  transducer
assembly (Biomechanical Engineering Laboratory, Sichuan
University,  Chengdu,  China)  and  a  fluid  reservoir.  The
pressure  transducer  assembly,  reservoir,  and  tubing  were
filled  with  Balanced  Salt  solution  (BSS)®  intraocular
irrigating  solution  (Alcon  Laboratories,  Fort  Worth,  TX)
before performing cannulation. Following cannulation, the
height of the reservoir relative to the eye was adjusted to
produce various pressure values (10, 15, 20, 25, 30, 35, and
40 mmHg, in random order) inside the eye. A researcher who
was masked to the height of the reservoir and the pressure
transducer readings used the TonoVet™ tonometer to obtain
pressure readings. Five readings were made at each preset
pressure for each eye.
Measurement  of  monkey  IOP:  Eight  (four  male  and  four
female) naïve rhesus monkeys (M3–M10) were used for IOP
studies. For IOP measurements, sedation was induced by an
intramuscular  injection  of  ketamine  (8  mg/kg;  Jiangsu
Hengrui Medicine Co. Ltd., Jiangsu, China). Each animal was
positioned in a seated posture in a custom-designed monkey
chair with arms gently restrained, and IOP for both eyes was
measured (Figure 1). Five readings were obtained per eye for
each condition, and the mean IOP value was calculated and
reported.
TABLE 1. INFORMATION OF MONKEYS USED IN THE STUDY.
ID # Age (years) Sex Weight (kg) Studies
M1 6 F 8.2 Tonometer validation
M2 6 M 7.8 Tonometer validation
M3 5 M 5 Diurnal and Drug Effects
M4 3 M 4.2 Diurnal and Drug Effects
M5 5 M 5.2 Diurnal and Drug Effects
M6 3 M 5.8 Diurnal and Drug Effects
M7 2 F 4.2 Diurnal and Drug Effects
M8 3 F 3.8 Diurnal and Drug Effects
M9 5 F 5.2 Diurnal and Drug Effects
M10 2 F 4.2 Drug Effects
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Switzerland) was dissolved in BSS to a final concentration of
0.05%  (w/v).  One  drop  (30  μl)  of  the  solution  was
administrated topically to the right eye of six animals whereas
the vehicle was administrated to the left eye. Assessments of
the IOP were performed at 0 h (before drug treatment) as well
as 2 h, 4 h, and 6 h post-treatment.
Travatan® ophthalmic solution (Alcon) or Eyestream®
ocular irrigation solution (Alcon), which served as a control,
was instilled ocular topically in a masked fashion to assigned
monkey eyes. Half of the animals (two males and two females)
were  treated  with  1  drop  (30  μl)  of  Travatan®  (0.004%
travoprost) on their right eye and the remaining half was
treated on their left eye. The contralateral eye received 1 drop
(30 μl) of Eyestream®. In the first study, a single treatment
was administered at 10:00 AM (0 h) immediately after a
baseline IOP measurement. Post-treatment IOP was assessed
at 2 h, 7 h, 23 h, and 47 h. In the second study, both Travatan®
and Eyestream® (both 30 μl) were administered daily at 10:00
AM for three consecutive days (0 h, 24 h, and 48 h), and IOPs
were measured at 0 h (immediately before the 0 h dosing), 24
h (immediately before the 24 h dosing), 48 h (immediately
before the 48 h dosing), 72 h, and 96 h.
Data analysis: Linear regression was used to evaluate linear
correlation between the measured and actual IOP values in the
tonometer validation studies. Comparison of the IOP values
at various time points in the diurnal IOP fluctuation study was
performed by one-way ANOVA. Two-tailed paired Student’s
t-test was used to compare IOPs between drug- and vehicle-
treated eyes. Data are reported as mean±standard error of
Figure 1. IOP measurement using TonoVet™. Each monkey was
positioned in a custom-designed monkey chair with arms gently
restrained, and IOP was measured with the TonoVet™ tonometer
according to the manufacturer’s recommended procedures.
mean (SEM). Differences are regarded as significant when
p<0.05.
RESULTS
Tonometer validation: The TonoVet™ rebound tonometer
generated IOP readings that correlated very well in a linear
relationship with the preset IOP values, which were confirmed
by  the  pressure  transducer  assembly.  An  example  of  the
tonometer readings at each preset IOP is shown in Figure 2A.
The  correlation  was  reproducible  in  independent
measurements from three additional monkey eyes, each with
a regression coefficient (r2) between 0.968 and 0.996 (Figure
2B). The slopes and y-intercepts of the regression lines were
0.922±0.014  (mean±SEM,  n=4)  and  3.04±0.61  mmHg,
respectively. The correlation coefficient of the combined data
is r2=0.97. Importantly, although the values obtained by the
equipment  had  good  correlation  with  the  actual  IOP,
systematic errors were evidenced. The mean slope and y-
intercepts were statistically significantly different from 1 and
0  (both  p<0.01),  respectively.  To  adjust  for  the  minor
systematic  error,  all  subsequent  IOP  measurements  were
corrected  according  to  the  following  equation:  actual
IOP=(Measured IOP–3.04 mmHg)/0.922.
Diurnal IOP fluctuation: A trend of diurnal IOP fluctuation
of  the  rhesus  monkey  was  detectable  using  the  rebound
tonometer. Measurements of IOP were conducted at 9:00 AM,
noon, 3:00 PM, 6:00 PM (immediately before lights off), and
9:00 PM in the same day. For the 9:00 PM measurement,
sedation and IOP measurement were performed under very
dim light. The lowest IOP values were recorded at noon and
6:00 PM (17.0±0.7 mmHg and 16.9±0.6 mmHg, respectively;
mean±SEM, n=14 eyes of seven monkeys). The IOP peaked
Figure  2.  Correlation  between  IOP  readings  obtained  by  the
TonoVet™  tonometer  and  the  actual  IOP  values.  Eyes  of  two
anesthetized monkeys were cannulated and perfused with BSS. Their
IOPs were manipulated by changing the height of the perfusate
reservoir.  TonoVet™  readings  were  obtained  by  a  researcher
unaware of the actual IOP. A: Examples of individual IOP readings
of a randomly selected eye (Eye number: M1R; right eye of monkey
M1). Each symbol represents a single reading. B: Mean IOP values
of TonoVet™ tonometer measurements for each of the four tested
monkey  eyes.  M1R  and  M1L  represent  the  right  and  left  eye,
respectively, of monkey M1. M2R and M2L represent the right and
left eye, respectively, of monkey M2.
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Figure 3). However, the differences in IOPs at the various time
points were not statistically significant (p>0.05 by one-way
ANOVA).
Effect  of  H1152  on  monkey  IOP:  To  determine  if  the
TonoVet™  tonometer  is  useful  in  assessing  IOP  changes
induced by pharmacologically active compounds, eyes of six
monkeys were treated with H1152, a well known rho kinase
inhibitor  and  ocular  hypotensive.  As  shown  in  Figure  4,
topical ocular administration of H1152 (15 μg, 30 μl of a
0.05%  solution)  produced  a  profound  reduction  in  IOP
compared to the vehicle-treated eyes: 5.5 mmHg (p<0.01) at
2 h, 5.9 mmHg (p<0.001) at 4 h, and 3.5 mmHg (p>0.05) at 6
h. These findings indicate that the instrument was effective in
detecting drug-induced IOP changes in the monkey eye.
Effects  of  Travatan®  on  monkey  IOP:  The  TonoVet™
tonometer  was  also  useful  in  revealing  the  IOP-lowering
effect of Travatan®, a widely used ocular hypotensive drug
that is approved for use in humans. Administration of a single
drop (30 μl) of Travatan® onto the eye produced a transient
but  not  statistically  significant  (p=0.26)  IOP  increase
(1.1 mmHg) 2 h after treatment in monkeys under sedation.
This tendency of ocular hypertension disappeared at 7 h. At
23 h, the Travatan®-treated eyes had a significantly (p<0.05)
lowered IOP (−2.4 mmHg) compared to the placebo-treated
eyes.  The  IOP  reduction  produced  by  Travatan®  became
insignificant 48 h after treatment (Figure 5).
These  findings  were  confirmed  by  a  second  study  in
which daily treatments with Travatan® were administered in
three  consecutive  days.  As  demonstrated  in  Figure  5,  the
rebound tonometer recorded a significant (p<0.05 or p<0.01)
reduction in IOP (ranging from −2.0 mmHg to −2.2 mmHg)
Figure 3. Normal diurnal IOP fluctuation in the rhesus monkey.
Ketamine-treated animals were subjected to IOP measurement by the
TonoVet™ tonometer at the indicated times of the day. Symbols
represent mean±SEM (n=14).
24 h after each treatment. The drug effect vanished 48 h after
the last drug treatment (Figure 6).
DISCUSSION
In this study, we reported the characterization and validation
of the TonoVet™ rebound tonometer, a newly developed
tonometer,  in  measuring  IOP  in  rhesus  monkeys.  In  the
validation  studies,  using  procedures  recommended  by  the
manufacturer, we observed linear correlations with very high
correlation coefficients between the measured IOP values and
the actual pressure within the eye. We further found that the
measured IOP tended to overestimate slightly at lower actual
IOP values and underestimate at higher IOP values such that
the slope of the regression line was smaller than 1 while the
y-intercept  was  larger  than  0.  To  compensate  for  this
systematic  error  and  calculate  the  actual  IOP,  correction
factors were needed.
With  this  equipment,  we  could  detect  diurnal  IOP
fluctuations in the sedated rhesus monkeys. In this study, IOP
was lower at noon and 6:00 PM and higher at 3:00 PM and
9:00 PM with a 1.2 mmHg difference between them. Our
findings of a higher IOP in the afternoon agree with published
reports. For example, Bito et al. [11] showed that the IOP of
free-breeding young rhesus monkeys peaked between 2–3
PM. Similarly, the IOP of cynomolgus monkeys was also
higher between 2:00 PM and 4:00 PM [12]. In addition, our
observations of lower IOP at noon and 6:00 PM corroborate
with these previous reports. However, these investigators also
observed an additional high level of IOP in the morning [11,
12], which we did not detect. Furthermore, the current trend
Figure 4. Effect of H1152 (15 μg) on monkey IOP. H1152 or vehicle
was administered topically on assigned eyes at 0 h. Assessment of
IOP  was  conducted  by  a  researcher  who  was  unaware  of  the
treatments at 0 h immediately before dosing and at 2 h, 4 h, and 6 h
post-treatment. Error bars represent SEM of IOP values (n=6). The
double asterisk indicates p<0.01 and three asterisks denote p<0.001
between the two groups by paired Student’s t-test.
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between the highest and lowest IOP values, and no statistical
significance  was  reached  among  the  various  time  points.
These  disparities  may  be  related  to  sedation  during  IOP
measurement. To address this issue, we are training monkeys
to accept TonoVet™ measurements under conscious state
without sedation.
We evaluated the practicability of using the tonometer to
assess drug-induced IOP changes in the monkey. Our results
indicated  that  the  TonoVet™  was  sensitive  to  detect  the
effects of IOP-lowering drugs. For example, inhibitors of rho
kinase  (also  known  as  rho-associated  coiled  coil-forming
kinase or ROCK) were shown to reduce rabbit and monkey
IOP efficaciously by improving outflow facility [13-15]. In
the  current  study,  the  TonoVet™  demonstrated  the  IOP-
lowering effect of a prototypical rho kinase inhibitor, H1152,
in the rhesus monkey. The drug produced more than a 5-
mmHg decrease in IOP, which lasted for at least 4 h.
The TonoVet™ was further tested for its detection of IOP
change  generated  by  Travatan®,  which  contains  0.004%
travoprost.  Travoprost  is  the  prodrug  of  a  potent  FP
prostaglandin receptor agonist [16]. FP prostanoids such as
travoprost and latanoprost are potent and efficacious IOP-
lowering  drugs  in  humans  and  other  animals  [16,17].
Interestingly,  prostanoids  typically  cause  a  reduction  of
primate IOP including human with a 2–4 h lag time after
topical administration, and the effect lasted for at least 24 h
[18-21]. In the current study, we confirmed the prolonged
IOP-lowering effect of travoprost. However, we unexpectedly
Figure 5. Effect of a single dose of 30 μl Travatan® on monkey IOP.
Travatan® or Eyestream® (vehicle) was administered topically on
assigned eyes at 0 h (10:00 AM). Assessment of IOP was conducted
by a researcher who was unaware of the treatments at 0 h immediately
before dosing and 2 h, 7 h, 23 h, and 47 h post-treatment. The arrow
indicates when the treatment was applied. Error bars represent SEM
of IOP values (n=8). An asterisk indicates p<0.05 between the two
groups by paired Student’s t-test.
observed  a  transient  though  not  statistically  significant
increase  of  IOP  2  h  after  drug  administration.  To  our
knowledge, this initial, transient ocular hypertension was not
previously reported in the rhesus monkey. Nonetheless, this
phenomenon has been observed in the rat [22,23] and mouse
[24]. The mechanism of action of the ocular hypertensive
effect is unclear. And the discrepancies between these data are
yet to be reconciled, although the differences in basal IOP
levels  and  the  use  of  sedative  likely  contributed  to  the
intriguing observations.
In  summary,  we  found  that  monkey  IOP  readings
reported by the TonoVet™ rebound tonometer correlated well
with the actual IOP values. Only small correction factors were
needed to accurately estimate the actual IOP. The equipment
is a very practical tool for monkey IOP measurement. It is easy
to learn and convenient to use. It is non-invasive and well
tolerated by the animal. We showed in this study that up to
five measurements in one day and up to five consecutive daily
measurements were tolerable to the animal. These repeated
TonoVet™ readings did not cause any ocular abnormalities.
We also showed that the instrument could detect diurnal IOP
fluctuations commonly seen in mammals such as the rhesus
monkey. Moreover, we conducted masked experiments to
evaluate the feasibility of using the tonometer to monitor drug-
induced IOP change in the monkey. Our results indicated that
the TonoVet™ was able to discern the IOP-lowering effects
of H1152 and Travatan. Overall, our data demonstrated the
Figure 6. Effect of multiple doses of Travatan® on monkey IOP. One
drop  (30  μl)  of  Travatan®  or  Eyestream®  (placebo)  was
administered topically on assigned eyes at 0 h (10:00 AM), 24 h, and
48 h (indicated by the arrows). Assessment of IOP was conducted by
a masked researcher who was unaware of the treatments at 0 h
immediately before dosing, 24 h immediately before dosing, 48 h
immediately before dosing, 72 h, and 96 h post-treatment. Error bars
represent SEM of IOP values (n=8). An asterisk denotes p<0.05 and
a double asterisk denotes p<0.01 between the two groups by paired
Student’s t-test.
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measurement in rhesus monkeys.
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